Radiopaedia Helpers

Spacing

error

"In 2020, the cIMPACT-NOW Working Committee considered myxoid glioneuronal tumour to represent a distinct entity based on genetic mutations, imaging features and anatomic location; consequently naming it "myxoid glioneuronal tumour, PDGFRA p.K385- mutant" ³ and it is included in the 5^th Edition (2021) WHO brain tumour classification ⁵."

Line 4:243 · 'p.K' should have one space.

Strong List Colon Position

error

"T2: hyperintense"

Line 28:8 · When enboldening an intro, the colon should not be bold. 'T2: hyperintense'

"T1 C+ (Gd): no enhancement"

Line 30:8 · When enboldening an intro, the colon should not be bold. 'T1 C+ (Gd): no'

Acronyms

warning

"In 2020, the cIMPACT-NOW Working Committee considered myxoid glioneuronal tumour to represent a distinct entity based on genetic mutations, imaging features and anatomic location; consequently naming it "myxoid glioneuronal tumour, PDGFRA p.K385- mutant" ³ and it is included in the 5^th Edition (2021) WHO brain tumour classification ⁵."

Line 4:25 · 'NOW' has no definition. Spell it out if it's unfamiliar to the audience.

"OLIG2, SOX10, GFAP: positive"

Line 20:43 · 'GFAP' has no definition. Spell it out if it's unfamiliar to the audience.

Emphasis

warning

"Myxoid glioneuronal tumour is negative to BRAF and FGFR1 mutations or rearrangements, which distinguish DNETs, rosette-forming glioneuronal tumours (RGNTs) and other low-grade neuroepithelial tumours. Ki-67 index ranges from 1% to 4% ¹."

Line 21:46 · Italics should be used only in exceptional circumstances: 'BRAF'

Strong

warning

"MRI "

Line 24:5 · Generally, don't use bold in text: 'MRI '

Headings Valid

warning

Expected headings

H1 Terminology
H1 Usage
H1 Epidemiology
H2 Risk factors
H2 Associations
H1 Clinical presentation
H2 Complications
H1 Diagnosis
H2 Diagnostic criteria
H2 Diagnostic clues
H1 Pathology
H2 Aetiology
H2 Location
H2 Classification
H2 Macroscopic appearance
H2 Microscopic appearance
H2 Immunophenotype
H2 Markers
H2 Genetics
H1 Radiographic features
H2 Plain radiograph
H2 Mammography
H2 Antenatal ultrasound
H2 Transoesophageal echocardiography
H2 Ultrasound
H2 CT
H3 Dual-energy CT
H2 Angiography (DSA)
H2 MRI
H2 CT/MRI
H2 Nuclear medicine
H3 PET-CT
H3 PET-MRI
H1 Radiology report
H1 Treatment and prognosis
H2 Complications
H1 History and etymology
H1 Differential diagnosis
H2 Clinical differential diagnosis
H1 Practical points
H1 See also

"MRI "

Line 24:1 · "MRI " is not a recognised heading for this article type.

Semicolons

suggestion

"In 2020, the cIMPACT-NOW Working Committee considered myxoid glioneuronal tumour to represent a distinct entity based on genetic mutations, imaging features and anatomic location; consequently naming it "myxoid glioneuronal tumour, PDGFRA p.K385- mutant" ³ and it is included in the 5^th Edition (2021) WHO brain tumour classification ⁵."

Line 4:182 · Use semicolons judiciously.

Oxford Comma

suggestion

"Although it has been designated as a WHO grade 1 tumour in the WHO brain tumour classification, myxoid glioneuronal tumour tends to recur, progress or disseminate in the ventricles. They may cause critical mass and compressive effect with obstructive hydrocephalus ¹."

Line 8:143 · Use the Oxford comma in 'recur, progress or disseminate'.

"Data regarding prognosis for myxoid glioneuronal tumour are limited given the rarity of this entity. Surgical resection is often curative, although cases of recurrence, progression and intraventricular dissemination have been described. In these cases a second resection was frequently necessary. Only seldomly have radiotherapy and chemotherapy been used ¹."

Line 33:161 · Use the Oxford comma in 'recurrence, progression and intraventricular'.

Lint: myxoid-glioneuronal-tumour